GNPX Insider Trading
Insider Ownership Percentage: 0.44%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
Genprex Share Price & Price History
Current Price: $2.33
Price Change: ▼ Price Decrease of -0.1 (-4.12%)
As of 12/17/2025 04:59 PM ET
Genprex Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/21/2023 | Catherine M Vaczy | EVP | Buy | 10 | $2,140.00 | $21,400.00 | 132 |  |
| 4/21/2023 | John Rodney Varner | CEO | Buy | 9 | $2,100.00 | $18,900.00 | 10 | |
Genprex Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 11/17/2025 | Susquehanna International Group LLP | 340,056 | $58K | 0.0% | +11.7% | 27.204% |  |
| 2/12/2025 | Geode Capital Management LLC | 76,045 | $65K | 0.0% | +368.1% | 0.894% | |
| 2/11/2025 | Virtu Financial LLC | 80,424 | $68K | 0.0% | +64.1% | 0.945% | |
| 8/15/2024 | Armistice Capital LLC | 218,000 | $0.41M | 0.0% | +122.7% | 10.386% | |
| 11/6/2023 | AMH Equity Ltd | 813,135 | $0.32M | 0.4% | N/A | 1.369% | |
| 5/9/2023 | Verus Capital Partners LLC | 55,500 | $51K | 0.0% | -37.3% | 0.107% | |
| 2/13/2023 | Tcwp LLC | 17,500 | $25K | 0.0% | N/A | 0.036% | |
| 5/13/2022 | TCG Advisory Services LLC | 16,000 | $36K | 0.0% | N/A | 0.033% | |
| 5/11/2022 | GSA Capital Partners LLP | 123,618 | $0.28M | 0.0% | -59.3% | 0.258% | |
| 2/14/2022 | GSA Capital Partners LLP | 303,904 | $0.40M | 0.0% | -25.8% | 0.636% | |
| 1/14/2022 | Spire Wealth Management | 40,000 | $52K | 0.0% | +60.0% | 0.084% | |
| 11/15/2021 | GSA Capital Partners LLP | 409,644 | $1.10M | 0.1% | N/A | 0.862% | |
| 11/12/2021 | Renaissance Technologies LLC | 615,055 | $1.65M | 0.0% | -2.3% | 1.294% | |
| 11/12/2021 | Geode Capital Management LLC | 375,205 | $1.01M | 0.0% | +4.6% | 0.789% | |
| 11/12/2021 | B. Riley Wealth Management Inc. | 16,750 | $45K | 0.0% | N/A | 0.035% | |
| 11/9/2021 | BlackRock Inc. | 539,544 | $1.45M | 0.0% | -1.6% | 1.135% | |
Data available starting January 2016
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Read More on Genprex
Volume
82,855 shs
Average Volume
278,077 shs
Market Capitalization
$5.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
Who are the major institutional investors of Genprex?
Which major investors are buying Genprex stock?
In the previous quarter, GNPX stock was acquired by institutional investors including:
- Susquehanna International Group LLP
